erlotinib hydrochloride has been researched along with vorinostat in 8 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (vorinostat) | Trials (vorinostat) | Recent Studies (post-2010) (vorinostat) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 2,529 | 181 | 1,840 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | vorinostat (IC50) |
|---|---|---|---|
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Histone deacetylase 8 | Schistosoma mansoni | 1.3147 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Gli1 | Mus musculus (house mouse) | 2.23 | |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.7472 | |
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 1.55 | |
| Histone deacetylase 1 | Mus musculus (house mouse) | 0.1121 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.3382 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.2644 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.0382 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.456 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.5 | |
| Tubulin beta chain | Sus scrofa (pig) | 1.5 | |
| Albumin | Homo sapiens (human) | 0.1072 | |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 4.66 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.0903 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.011 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.24 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.1582 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.053 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.116 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Leukotriene A-4 hydrolase | Mus musculus (house mouse) | 6.15 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.042 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.13 | |
| Delta-type opioid receptor | Homo sapiens (human) | 7.2 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7.2 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.6096 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.086 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.322 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.2701 | |
| Histone deacetylase 1 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.07 | |
| Renin | Macaca fascicularis (crab-eating macaque) | 0.067 | |
| Histone deacetylase 3 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 1 | |
| Histone deacetylase | Plasmodium falciparum 3D7 | 0.1 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6115 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3746 | |
| HD2 type histone deacetylase HDA106 | Zea mays | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.4211 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.5235 | |
| Carboxypeptidase B2 | Homo sapiens (human) | 0.362 | |
| Histone deacetylase 7 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 6 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 4 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.9141 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2634 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5614 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.5926 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0945 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.0905 | |
| Histone deacetylase 6 | Mus musculus (house mouse) | 0.3742 | |
| Histone deacetylase | Zea mays | 0.029 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlson, RH | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Kim, C; Lee, KB; Shah, BP; Subramaniam, P | 1 |
| Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M | 1 |
| Choi, EK; Hong, SW; Hong, YS; Hwang, IY; Jin, DH; Kim, JE; Kim, JH; Kim, KP; Kim, SM; Kim, TW; Lee, DH; Lee, EY; Lee, JS; Lee, WK; Moon, JH; Park, SJ; Shin, JS; Shin, YJ | 1 |
| Connelly, JW; Doroshow, JH; Fang, J; Fogli, LK; Hamed, H; Harris, E; Hose, C; Konaté, MM; Krushkal, J; Li, MC; Miller, SB; Monks, A; Palmisano, A; Polley, EC; Rapisarda, A; Simon, R; Simpson, MA; Sonkin, D; Teicher, BA; Voth, AR; Wu, X; Zhao, Y | 1 |
| Gao, WW; Hao, JQ; Ma, T; Sun, CL; Wu, PF | 1 |
| Abdel-Ghany, S; Alqosaibi, AI | 1 |
1 trial(s) available for erlotinib hydrochloride and vorinostat
| Article | Year |
|---|---|
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat | 2014 |
7 other study(ies) available for erlotinib hydrochloride and vorinostat
| Article | Year |
|---|---|
American Association for Cancer Research 100th Annual Meeting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Male; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research; Societies, Medical; United States; Vorinostat | 2009 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Compounding; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Ligands; Neoplasm Proteins; Particle Size; PC12 Cells; Quinazolines; Rats; RNA, Small Interfering; Vorinostat | 2011 |
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Vorinostat | 2016 |
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Early Growth Response Protein 1; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Internet; National Cancer Institute (U.S.); Oligonucleotide Array Sequence Analysis; Signal Transduction; Translational Research, Biomedical; United States; Vorinostat | 2018 |
Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 10; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Tensins; Vorinostat; Xenograft Model Antitumor Assays | 2020 |
Vorinostat induces G2/M cell cycle arrest in breast cancer cells via upregulation of PTEN.
Topics: Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; PTEN Phosphohydrolase; Transcriptional Activation; Up-Regulation; Vorinostat | 2023 |